Research programme: thrombopoietin agonists - NascaCell Technologies

Drug Profile

Research programme: thrombopoietin agonists - NascaCell Technologies

Alternative Names: SE-ET-TPO20d; Thrombo plus

Latest Information Update: 18 May 2011

Price : $50

At a glance

  • Originator NascaCell Technologies
  • Class Proteins
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombocytopenia

Most Recent Events

  • 18 May 2011 Discontinued - Preclinical for Thrombocytopenia in Germany (Parenteral)
  • 21 Aug 2006 Preclinical trials in Thrombocytopenia in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top